News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
107last 24h
3127last 7d
512● bullish (7d)
311● bearish (7d)
227publishers
Simply Wall St.4d agoneutral
How Investors May Respond To ImmunityBio (IBRX) Europe Launch And Trial ProgressSimply Wall St.4d agoneutral
ImmunityBio (IBRX) Could Be 42% Below Fair Value After Trial Database LockMT Newswires4d agoneutral
ImmunityBio Treats First Patients in Europe With Anktiva for Invasive Bladder CancerStocktwits18d agoneutral
ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing NearsSimply Wall St.20d agoneutral
ANKTIVA Label Expansion Could Change The Case For ImmunityBio StockInsider Monkey39d agoneutral
A $5.8B Cancer Market Opportunity Is Emerging - Why GA-Courtenay Favors ImmunityBio (IBRX)Insider Monkey47d agoneutral
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%